Jade Biosciences, Inc.(JBIO)

Biotechnology · Waltham, MA

$13.32-0.75 (-5.32%)

Delayed quote: Oct 6, 2026, 1:05 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T17:07:34.356Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:07:34.356Z.

Quote observation: 2026-10-06T17:05:06.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -164,702,000
Quote market capitalization: 810,714,355
Total debt · period ending 2026-06-30: 628,000
Cash · period ending 2026-06-30: 107,250,000

FMP input reference: 7de7752a9f7c92cf302168b3adc2b8952dbd3ee015c15fa7e623ade4200d4f53

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

JBIO EBITDA Yield Metrics

EBITDA YIELD

N/A

JBIO Competitors' EBITDA Yield

JBIO

Jade Biosciences, Inc.

Current

Market Cap

$810.71M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INMD

InMode Ltd.

vs JBIO

Market Cap

$804.32M

EBITDA Yield

16.94%

TTM Avg

14.19%

3Y Avg

12.45%

5Y Avg

9.40%

ARDX

Ardelyx, Inc.

vs JBIO

Market Cap

$800.37M

EBITDA Yield

N/A

TTM Avg

123.97%

3Y Avg

123.97%

5Y Avg

123.97%

AHCO

AdaptHealth Corp.

vs JBIO

Market Cap

$793.88M

EBITDA Yield

15.04%

TTM Avg

18.56%

3Y Avg

15.22%

5Y Avg

13.39%

PACB

Pacific Biosciences of California, Inc.

vs JBIO

Market Cap

$830.86M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GYRE

Gyre Therapeutics, Inc.

vs JBIO

Market Cap

$789.34M

EBITDA Yield

N/A

TTM Avg

1.34%

3Y Avg

2.25%

5Y Avg

2.25%

GERN

Geron Corporation

vs JBIO

Market Cap

$789.07M

EBITDA Yield

N/A

TTM Avg

0.13%

3Y Avg

0.13%

5Y Avg

0.13%

BBNX

Beta Bionics, Inc.

vs JBIO

Market Cap

$833.66M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALMS

Alumis Inc.

vs JBIO

Market Cap

$835.64M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GLUE

Monte Rosa Therapeutics, Inc.

vs JBIO

Market Cap

$839.73M

EBITDA Yield

N/A

TTM Avg

3.15%

3Y Avg

3.15%

5Y Avg

3.15%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Jade Biosciences, Inc. (JBIO)	$810.71M	N/A	N/A	N/A	N/A
InMode Ltd. (INMD)vs ›	$804.32M	16.94%	14.19%	12.45%	9.40%
Ardelyx, Inc. (ARDX)vs ›	$800.37M	N/A	123.97%	123.97%	123.97%
AdaptHealth Corp. (AHCO)vs ›	$793.88M	15.04%	18.56%	15.22%	13.39%
Pacific Biosciences of California, Inc. (PACB)vs ›	$830.86M	N/A	N/A	N/A	N/A
Gyre Therapeutics, Inc. (GYRE)vs ›	$789.34M	N/A	1.34%	2.25%	2.25%
Geron Corporation (GERN)vs ›	$789.07M	N/A	0.13%	0.13%	0.13%
Beta Bionics, Inc. (BBNX)vs ›	$833.66M	N/A	N/A	N/A	N/A
Alumis Inc. (ALMS)vs ›	$835.64M	N/A	N/A	N/A	N/A
Monte Rosa Therapeutics, Inc. (GLUE)vs ›	$839.73M	N/A	3.15%	3.15%	3.15%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

JBIO EBITDA Yield Metrics

JBIO Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics